Last updated: September 2, 2026
Metyrapone is a low-volume, specialist endocrine drug used primarily for Cushing syndrome and diagnostic assessment of the hypothalamic-pituitary-adrenal axis. Its commercial market is constrained by limited patient volume, specialist prescribing, competing therapies, and the absence of meaningful current patent protection. Recordati, through its acquisition of HRA Pharma Rare Diseases, controls the principal branded commercial platform for Metopirone in European markets, but the company does not separately disclose metyrapone revenue.
The product has durable clinical relevance because it directly inhibits 11-beta-hydroxylase and can reduce cortisol production rapidly. Its financial profile is different from that of newer Cushing syndrome therapies: metyrapone has low development risk and limited manufacturing complexity, but also limited pricing power and minimal exclusivity protection.
What is metyrapone used for and how large is its market?
Metyrapone is an oral steroidogenesis inhibitor used to reduce cortisol production in patients with endogenous Cushing syndrome. It is also used in diagnostic testing of the adrenal-pituitary axis, although diagnostic use has declined as alternative testing methods have become established.
Metyrapone inhibits CYP11B1, also known as 11-beta-hydroxylase. The inhibition reduces conversion of 11-deoxycortisol to cortisol and 11-deoxycorticosterone to corticosterone. The drug can produce a rapid reduction in cortisol, making it useful when surgery is delayed, contraindicated, or insufficient.
Its addressable market is small relative to major endocrinology products because:
- Endogenous Cushing syndrome is rare.
- Surgery is the preferred curative treatment for many patients.
- Metyrapone is used mainly in specialist centers.
- Treatment is often episodic, bridging, or combination therapy.
- Long-term tolerability and androgenic or mineralocorticoid effects can limit use.
The European Medicines Agency classifies Metopirone as a product for a rare disease indication in the European Union. The product is authorized for diagnostic use and treatment of endogenous Cushing syndrome in several European markets, subject to national reimbursement and labeling conditions.[1]
Metyrapone commercial profile
| Attribute |
Market assessment |
| Active ingredient |
Metyrapone |
| Branded product |
Metopirone |
| Main commercial holder |
HRA Pharma Rare Diseases, now within Recordati |
| Primary indication |
Endogenous Cushing syndrome |
| Diagnostic use |
Adrenal-pituitary function testing |
| Dosage form |
250 mg hard capsules |
| Administration |
Oral |
| Main markets |
Europe and selected international markets |
| U.S. position |
Limited or no broad branded commercial presence compared with European markets |
| Patent status |
Original composition and use rights are expired |
| Current moat |
Regulatory know-how, supply reliability, specialist relationships, and market familiarity |
Who owns metyrapone and Metopirone?
Recordati acquired the European specialty pharmaceutical business of HRA Pharma in 2021 for approximately €1.1 billion. The transaction included HRA Pharma Rare Diseases and its portfolio of specialty and rare-disease products, including Metopirone in relevant markets.[2]
HRA Pharma had previously acquired rights to Metopirone from Novartis in 2011. The transaction gave HRA commercial control of the product in several territories and expanded its rare-disease portfolio.[3]
The ownership chain is commercially important because metyrapone is not a new molecular entity with a single global patent owner. Market control depends on territorial marketing authorizations, supply arrangements, and local registration rights.
Ownership timeline
| Period |
Commercial event |
| 1950s |
Metyrapone developed as a steroidogenesis inhibitor |
| 1960s onward |
Clinical use established in adrenal-axis testing and Cushing syndrome |
| 2011 |
HRA Pharma acquired rights to Metopirone from Novartis in designated markets |
| 2021 |
Recordati acquired HRA Pharma, including the HRA Pharma Rare Diseases portfolio |
| Current |
Recordati is the principal branded commercial operator in Europe and selected territories |
When does metyrapone lose exclusivity?
Metyrapone lost composition-of-matter exclusivity decades ago. The molecule was first developed in the mid-20th century, so no original patent protection remains commercially relevant.
There is no current basis for treating metyrapone as a patent-protected new chemical entity. Any product-level exclusivity would have to arise from a later formulation, method of use, manufacturing process, or jurisdiction-specific regulatory right. Public product information does not indicate a current, broad patent estate that materially blocks generic or alternative supply.
The practical exclusivity position is therefore:
| Exclusivity category |
Current position |
| Composition-of-matter patent |
Expired |
| Original therapeutic-use patents |
Expired |
| New chemical entity exclusivity |
None |
| Orphan-drug exclusivity |
No broad current exclusivity identified |
| Pediatric exclusivity |
None identified |
| Data exclusivity |
Historical periods expired or not commercially controlling |
| Formulation exclusivity |
No broad, high-value estate publicly evident |
| Regulatory exclusivity |
Depends on jurisdiction and authorization history |
What patents protect metyrapone and Metopirone?
No active foundational patent is expected to protect the metyrapone molecule. The original chemistry and pharmacology are prior art.
The most relevant intellectual-property questions concern later commercial rights rather than molecular ownership:
- Whether a specific capsule formulation has a live patent.
- Whether a particular dosing regimen is claimed.
- Whether manufacturing specifications or impurity controls are protected.
- Whether a local marketing authorization creates practical barriers unrelated to patents.
- Whether a supplier has confidential know-how covering synthesis, purification, or scale-up.
For conventional 250 mg capsules, patent barriers appear limited. A generic manufacturer would more likely face regulatory, supply-chain, pharmacovigilance, and market-size barriers than a blocking composition patent.
Formulation patents and manufacturing barriers
Metyrapone is a relatively old, orally administered small molecule. The product does not require biologic manufacturing, sterile filling, a complex delivery device, or cold-chain distribution. These characteristics reduce technical barriers to entry.
Potential manufacturing controls include:
- Raw-material qualification.
- Control of related substances and degradation products.
- Capsule-content uniformity.
- Stability under long-term storage.
- Validation of analytical methods.
- Consistent supply of active pharmaceutical ingredient.
- Compliance with current good manufacturing practice requirements.
These controls can delay entry or create supply problems, but they do not provide the same protection as a complex injectable formulation or a biologic manufacturing platform.
What is the FDA regulatory status of metyrapone?
Metyrapone has a different regulatory profile in the United States and Europe.
In Europe, Metopirone has established authorization for diagnosis and treatment of endogenous Cushing syndrome, with national implementation and prescribing conditions based on the applicable marketing authorization.[1]
In the United States, availability has historically been narrower. Metyrapone has been used in specialized endocrine practice and may be accessed through hospital, specialty, or alternative supply channels. The U.S. regulatory position should be assessed through current FDA Drugs@FDA, Orange Book, drug-shortage, and labeling databases because commercial availability and listing status can change independently of the underlying clinical literature.[4][5]
Orange Book and Paragraph IV exposure
The Orange Book is relevant only where an approved U.S. drug application and listed reference product exist. A conventional European Metopirone authorization does not automatically create a U.S. Orange Book reference product.
The commercial implications are:
- If no active U.S. reference listed drug exists, a standard ANDA pathway may not be available for that product in the ordinary manner.
- If a U.S. reference product is listed, generic applicants could challenge listed patents through Paragraph IV certifications.
- Because the original molecule is old, any Paragraph IV dispute would likely focus on formulation, labeling, or method-of-use claims rather than the active ingredient.
- No major publicly recognized U.S. Paragraph IV litigation campaign has defined the metyrapone market.
A U.S. entrant could face a regulatory pathway that is more complicated than a straightforward generic substitution, particularly if the reference product, labeling, or commercial supply status is unclear.
Which companies compete with metyrapone?
Metyrapone competes in the medical management of hypercortisolism rather than against a single direct substitute.
Key pharmacologic competitors
| Product |
Active ingredient |
Company or commercial origin |
Competitive role |
| Metopirone |
Metyrapone |
Recordati/HRA Pharma |
Rapid cortisol synthesis inhibition |
| Isturisa |
Osilodrostat |
Recordati |
Direct 11-beta-hydroxylase inhibitor; newer chronic-treatment option |
| Signifor |
Pasireotide |
Novartis |
Pituitary-directed therapy |
| Korlym |
Mifepristone |
Corcept Therapeutic |
Glucocorticoid receptor antagonist |
| Ketoconazole products |
Ketoconazole |
Multiple manufacturers |
Off-label steroidogenesis inhibition in some markets |
| Levoketoconazole products |
Levoketoconazole |
Xeris Biopharma |
Approved treatment option in the U.S. |
| Mitotane |
Mitotane |
Multiple regional suppliers |
Adrenolytic therapy, especially in adrenal malignancy contexts |
Osilodrostat is the closest newer pharmacologic competitor because it also inhibits 11-beta-hydroxylase. It has a more modern regulatory and commercial platform, but its adverse-effect profile and monitoring requirements differ from those of metyrapone.[6]
Metyrapone retains advantages in rapid cortisol reduction, clinical familiarity, and use in acute or preoperative management. Its disadvantages include androgen excess, hypertension or edema related to steroid precursors, and the need for biochemical monitoring.
How does metyrapone compare with osilodrostat?
| Factor |
Metyrapone |
Osilodrostat |
| Molecular age |
Old generic molecule |
Modern approved specialty drug |
| Main commercial brand |
Metopirone |
Isturisa |
| Patent position |
Foundational patents expired |
Later-generation patent and regulatory estate |
| Onset |
Rapid |
Rapid, with chronic treatment use |
| Chronic use |
Established but specialist-driven |
More commercially structured |
| Pricing power |
Low to moderate |
Higher |
| Manufacturing complexity |
Conventional oral capsule |
Conventional oral tablet, but newer regulatory package |
| Competitive risk |
From newer cortisol-lowering drugs |
From older low-cost drugs and other specialty therapies |
| Revenue visibility |
Not separately disclosed |
Included in Recordati specialty portfolio reporting |
Osilodrostat has a stronger current commercial platform because it is newer and has more recent regulatory exclusivity and intellectual-property support. Metyrapone remains relevant where clinicians prioritize speed, experience, or cost.
What is the financial trajectory for metyrapone?
No public company reports standalone global revenue, unit volume, gross margin, or operating profit for metyrapone. Recordati reports at portfolio and company level rather than by individual legacy product.
Recordati's overall business has expanded through specialty pharmaceuticals, rare diseases, and the HRA Pharma acquisition. The company reported total revenue of approximately €2.1 billion in 2023, reflecting the scale of the broader group rather than the contribution of Metopirone.[7]
Metyrapone is likely a small product within that portfolio. Its financial profile has several defining characteristics:
- Low research and development burden because the molecule is mature.
- Limited clinical-trial spending outside lifecycle management.
- Low or moderate manufacturing cost for the capsule dosage form.
- Specialist pricing in some countries.
- Small patient population.
- Limited opportunity for volume growth.
- Potentially attractive gross margin if supply is reliable.
- Exposure to reimbursement restrictions and hospital procurement.
The product can generate persistent cash flow despite modest sales because mature specialty drugs often require less promotional investment than newly launched products. The main risk is not patent expiry, which occurred long ago, but erosion of commercial relevance through newer drugs, generic supply, diagnostic substitution, and physician preference.
Revenue exposure and scenario analysis
| Scenario |
Commercial outcome |
| Base case |
Stable niche demand in European endocrine centers with limited growth |
| Upside case |
Greater use for preoperative control, severe hypercortisolism, or combination therapy |
| Downside case |
Substitution by osilodrostat, levoketoconazole, pasireotide, or lower-cost suppliers |
| Supply disruption case |
Temporary price and volume volatility, particularly in small national markets |
| Generic-entry case |
Price compression in markets with an established reference product and reimbursed generic pathway |
No defensible public figure supports assigning a specific percentage of Recordati revenue to metyrapone. Any such estimate would be speculative.
What patent litigation affects metyrapone?
No major, widely reported patent litigation campaign currently defines the metyrapone market. The absence of litigation is consistent with the molecule's age and limited commercial scale.
Potential disputes would more likely concern:
- Marketing authorization ownership.
- Distribution rights.
- Trademark use for Metopirone.
- Supply and quality agreements.
- National reimbursement decisions.
- Generic registration or substitution.
- Alleged infringement of a narrow formulation or dosing claim.
A conventional Paragraph IV battle would require a listed U.S. reference product and active patents in the Orange Book. Metyrapone does not have the litigation profile associated with high-value medicines such as GLP-1 agonists, oncology biologics, or long-acting injectables.
What generic entry risks exist for metyrapone?
Generic entry risk is structurally high because the active ingredient is old and the dosage form is relatively simple. The practical probability and timing of entry depend on the jurisdiction.
Main entry routes
- Conventional generic approval: Possible where a reference product and abbreviated pathway exist.
- National authorization: Relevant in European countries where the product is authorized through national or decentralized procedures.
- Hospital or specialty supply: Important where branded commercial distribution is limited.
- Compounding or extemporaneous preparation: May address supply gaps but does not necessarily create a fully substitutable commercial product.
- Importation: Can affect smaller markets where domestic registration is absent.
Generic competition may not produce immediate price collapse because market volume is small and manufacturers may have little incentive to enter. A single supplier can maintain a practical niche, while two or more approved suppliers would create stronger price pressure.
How strong is the metyrapone patent estate?
The patent estate is weak by modern specialty-pharmaceutical standards. Metyrapone has no meaningful remaining composition-of-matter exclusivity, no biologic manufacturing barrier, and no widely recognized late-stage formulation patent platform.
Its commercial protection is based on execution:
- Regulatory maintenance.
- Product quality.
- Reliable supply.
- Physician familiarity.
- Specialist distribution.
- National reimbursement positioning.
- Brand recognition in endocrine centers.
- Integration with Recordati's specialty sales infrastructure.
That protection can support a profitable niche product, but it does not support premium valuation based on long-term patent exclusivity.
What is the outlook for metyrapone?
Metyrapone should remain a durable but modest specialty product. Demand is supported by the continuing need for rapid cortisol control in Cushing syndrome, including patients awaiting surgery or requiring medical stabilization. Growth is constrained by the small disease population and competition from newer inhibitors and receptor-directed therapies.
The strongest commercial opportunities are likely to arise from:
- Increased diagnosis of endogenous Cushing syndrome.
- Greater use of combination therapy.
- Preoperative treatment.
- Hospital-based management of severe hypercortisolism.
- Expansion into markets where specialist access is improving.
The principal risks are generic or alternative supply, replacement by osilodrostat and levoketoconazole, national reimbursement pressure, and limited ability to expand beyond the established endocrine indication.
Key Takeaways
- Metyrapone is a mature oral steroidogenesis inhibitor marketed in Europe as Metopirone.
- Recordati controls the principal branded commercial platform through its HRA Pharma Rare Diseases business.
- Original patents have expired, and no broad current patent moat is evident.
- The product's market is small, specialist-driven, and concentrated in endocrine centers.
- Recordati does not separately disclose metyrapone revenue.
- Financial value comes from low development costs and persistent niche demand, not from high growth or patent exclusivity.
- Osilodrostat, levoketoconazole, pasireotide, mifepristone, ketoconazole, and mitotane are relevant competitive alternatives.
- Generic-entry risk is high in principle, but low market volume can limit manufacturer interest.
- No major current Paragraph IV or patent-litigation campaign is associated with metyrapone.
- The commercial outlook is stable to modestly declining, with upside tied to specialist use in severe or preoperative Cushing syndrome.
FAQs
Is metyrapone still commercially available?
Yes. Metopirone is commercially authorized in several European markets, although availability, reimbursement, and supply conditions vary by country.
Is metyrapone an orphan drug?
Metyrapone is used in the rare disease setting of endogenous Cushing syndrome, but its orphan-drug status and regulatory exclusivity must be assessed separately in each jurisdiction.
Does metyrapone have a generic version?
Generic or alternative supply may exist in selected markets. Availability depends on national registration, reference-product status, manufacturing capacity, and reimbursement rules.
Is metyrapone approved for long-term treatment?
Metyrapone can be used for ongoing control of endogenous Cushing syndrome under specialist supervision. Treatment duration depends on clinical response, adverse effects, biochemical monitoring, and the availability of surgery or alternative medicines.
Which company sells the competing drug Isturisa?
Isturisa, whose active ingredient is osilodrostat, is part of Recordati's specialty pharmaceutical portfolio. The product competes directly with metyrapone as an inhibitor of cortisol synthesis.
References
-
European Medicines Agency. (n.d.). Metopirone: EPAR product information. European Medicines Agency.
-
Recordati S.p.A. (2021). Recordati completes the acquisition of EUSA Pharma and HRA Pharma. Recordati.
-
HRA Pharma. (2011). HRA Pharma acquires Metopirone rights from Novartis. HRA Pharma.
-
U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs. U.S. Department of Health and Human Services.
-
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. U.S. Department of Health and Human Services.
-
U.S. Food and Drug Administration. (2020). Isturisa prescribing information. U.S. Department of Health and Human Services.
-
Recordati S.p.A. (2024). Annual report 2023. Recordati.
